TWI260316B - Production of chirally pure alpha-amino acids N-sulfonyl alpha-amino acids - Google Patents

Production of chirally pure alpha-amino acids N-sulfonyl alpha-amino acids Download PDF

Info

Publication number
TWI260316B
TWI260316B TW091135621A TW91135621A TWI260316B TW I260316 B TWI260316 B TW I260316B TW 091135621 A TW091135621 A TW 091135621A TW 91135621 A TW91135621 A TW 91135621A TW I260316 B TWI260316 B TW I260316B
Authority
TW
Taiwan
Prior art keywords
substituted
group
alkyl
acid
amino acid
Prior art date
Application number
TW091135621A
Other languages
English (en)
Chinese (zh)
Other versions
TW200306292A (en
Inventor
Lynn Resnick
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46204648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI260316(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/014,304 external-priority patent/US6610734B2/en
Priority claimed from US10/166,896 external-priority patent/US6657070B2/en
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200306292A publication Critical patent/TW200306292A/zh
Application granted granted Critical
Publication of TWI260316B publication Critical patent/TWI260316B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW091135621A 2001-12-11 2002-12-10 Production of chirally pure alpha-amino acids N-sulfonyl alpha-amino acids TWI260316B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/014,304 US6610734B2 (en) 2000-12-13 2001-12-11 Heterocyclic sulfonamide inhibitors of beta amyloid production
US10/166,896 US6657070B2 (en) 2000-12-13 2002-06-11 Production of chirally pure α-amino acids and N-sulfonyl α-amino acids

Publications (2)

Publication Number Publication Date
TW200306292A TW200306292A (en) 2003-11-16
TWI260316B true TWI260316B (en) 2006-08-21

Family

ID=46204648

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091135621A TWI260316B (en) 2001-12-11 2002-12-10 Production of chirally pure alpha-amino acids N-sulfonyl alpha-amino acids

Country Status (7)

Country Link
EP (1) EP1461332A4 (https=)
JP (1) JP4615861B2 (https=)
AU (2) AU2002351170B8 (https=)
CA (1) CA2470111A1 (https=)
MX (1) MXPA04005366A (https=)
TW (1) TWI260316B (https=)
WO (1) WO2003050062A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303857A3 (en) 2000-12-13 2007-07-30 Wyeth Corp Heterocyclic sulifonamide inhibitors of beta amyloid production
BRPI0408962A (pt) 2003-03-31 2006-04-04 Wyeth Corp inibidores sulfonamidas heterocìclicos contendo flúor- e trifluoroalquila da produção de beta amilóide e seus derivados
ES2330451T3 (es) 2004-01-16 2009-12-10 Wyeth Inhibidores a base de sulfonamidas heterociclicas de la produccion de beta-amiloides que contienen un azol.
JP2009534385A (ja) 2006-04-21 2009-09-24 ワイス キラル的に純粋なアミノアルコール中間体、それらの誘導体の製造、及びそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3802981A1 (de) * 1988-02-02 1989-08-10 Basf Ag Verfahren zur reduktion reduzierbarer verbindungen
US5264577A (en) * 1992-04-22 1993-11-23 Warner-Lambert Company Cyclic amino acids and derivatives thereof
ATE218541T1 (de) * 1992-08-25 2002-06-15 Searle & Co Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6191306B1 (en) * 1999-08-03 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylglycine

Also Published As

Publication number Publication date
WO2003050062A3 (en) 2003-11-20
AU2002351170B2 (en) 2009-09-24
WO2003050062A2 (en) 2003-06-19
MXPA04005366A (es) 2004-09-27
JP2005511727A (ja) 2005-04-28
EP1461332A2 (en) 2004-09-29
AU2009251195A1 (en) 2010-01-21
EP1461332A4 (en) 2009-10-21
CA2470111A1 (en) 2003-06-19
AU2002351170A1 (en) 2003-06-23
TW200306292A (en) 2003-11-16
AU2002351170B8 (en) 2009-10-08
JP4615861B2 (ja) 2011-01-19

Similar Documents

Publication Publication Date Title
US9024028B2 (en) Methods and compositions for the synthesis of multimerizing agents
JPH0245487A (ja) 新規ピロロ[1,4]ベンゾジアゼピン誘導体および老人性痴呆薬
TW200808770A (en) Novel processes for the preparation of DPP IV inhibitors
US11142499B1 (en) Method of preparing 5R-[(benzyloxy) amino] piperidine-2S-carboxylic acid or a derivative thereof
TW200403211A (en) Peptide deformylase inhibitors
CN112794860A (zh) 噁唑嘧啶酮酰胺类化合物或其可药用盐,制备方法及用途
US6657070B2 (en) Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
JPH07304770A (ja) 新規ベンゾアゼピノン誘導体
CN104788361B (zh) 5‑氮杂螺[2.4]庚烷‑6‑甲酸衍生物的合成方法
TWI260316B (en) Production of chirally pure alpha-amino acids N-sulfonyl alpha-amino acids
US7442793B2 (en) Peptide deformylase inhibitors
WO2020108415A1 (zh) 一种trk激酶抑制剂化合物的中间体化合物及制备方法
US7375120B2 (en) Peptide deformylase inhibitors
KR100788529B1 (ko) 3-(1-히드록시-펜틸리덴)-5-니트로-3h-벤조푸란-2-온,그의 제조 방법 및 용도
JP2009513697A (ja) ヒストンデアセチラーゼの阻害活性を有するアルキルカルバモイルナフタレニルオキシオクテノイルヒドロキシアミド誘導体およびその製造方法
JP4208463B2 (ja) キノロンカルボン酸誘導体の製造に関する中間体
US5252747A (en) Chiral quinolone intermediates
JP2003515600A (ja) {2−[4−(α−フェニル−p−クロロベンジル)ピペラジン−1−イル]エトキシ}酢酸の製法及びそのための新規な中間体
Doller et al. A practical preparation of (R)-and (S)-N-Boc-2-methylpiperidines
JPWO2004050654A1 (ja) ピロリジン化合物の合成とその塩
CA1237123A (en) Saturated bicyclic lactam acids and derivatives as cognition activators
JP5130211B2 (ja) 3−ヒドラジノ−2,5−ジオキソピロリジン−3−カルボキシレート類およびその製造方法ならびにその使用
US7884243B2 (en) Process for the synthesis of eneamide derivatives
CN120463652A (zh) 一种瑞博西尼中间体及其合成方法
CA3214107A1 (en) New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds